Gynaecological cancer: Vintafolide—targeting the folate receptor with a cytotoxic offers hope

  • Mina Razzak
  • Published 2013 in Nature Reviews Clinical Oncology

Abstract

Phase II data from the PRECEDENT trial has shown that women with platinumresistant ovarian cancer might gain some benefit with vintafolide, a new drug conjugate comprising desacetylvinblastine and folic acid. For these patients, who invariably have poor prognoses, this comes as welcome news. “Platinum-resistant ovarian cancer is difficult to treat and… (More)
DOI: 10.1038/nrclinonc.2013.201

Topics

Cite this paper

@article{Razzak2013GynaecologicalCV, title={Gynaecological cancer: Vintafolide—targeting the folate receptor with a cytotoxic offers hope}, author={Mina Razzak}, journal={Nature Reviews Clinical Oncology}, year={2013}, volume={10}, pages={668-668} }